Aptinyx Inc (APTX)

Trade APTX now with
1/16/2019 7:28:10 AM Aptinyx Says NYX-2925 Did Not Achieve Statistically Significant Separation From Placebo On Primary Endpoint
12/11/2018 8:28:00 AM Aptinyx To Present Preclinical Data On NYX-2925 At American College Of Neuropsychopharmacology’s Annual Meeting
12/3/2018 7:30:33 AM Aptinyx Reports Positive Results From Interim Analysis Of Exploratory Study Of NMDAr Modulator, NYX-2925
11/13/2018 7:47:29 AM Aptinyx Q3 Net Loss $14.2 Mln Or $0.43/shr Vs Net Loss Of $8.1 Mln Or $1.56/shr Last Year
11/12/2018 7:13:11 AM Aptinyx Studies Provide Evidence That NYX-2925 Elicits Persistent, NMDAr-Mediated Pharmacodynamic Activity In Humans
11/1/2018 7:28:49 AM Aptinyx Completes Enrollment In Phase 2 Study Of NYX-2925 For Painful Diabetic Peripheral Neuropathy
10/29/2018 8:11:58 AM Aptinyx To Present Preclinical Data On Novel NMDA Receptor Modulators At Annual Meeting Of The Society For Neuroscience
9/14/2018 8:08:19 AM Aptinyx Presents Preclinical Data On NMDA Receptor Modulator NYX-2925 At IASP
8/14/2018 6:29:26 AM Aptinyx Q2 Loss Per Share $1.83 Vs Loss $1.55 Last Year